Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Paclitaxel for Superficial Bladder Cancer
NCT00002917Phase 2Completed
- Sponsor
- Mary Babb Randolph Cancer Center
- Start
- Nov 1996
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in bladder cancer, sponsored by Mary Babb Randolph Cancer Center. Primary endpoints: Toxicity and safety of intravesical paclitaxel at 12 weeks, Efficacy against transitional cell carcinoma in situ (CIS) and/or unresectable papillary superficial bladder cancer at 6 months and 1 more. Started Nov 1996; status: completed.
02
Drugs
paclitaxel
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00002917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002917.